// App-Quantinova.ai

2053 : NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.

Researchers

Presenter

  • Andrew E. Sloan

Principal Investigators

  • Mark R. Gilbert

  • Peixin Zhang

  • Kenneth D. Aldape

  • Jing Wu

  • Lisa R. Rogers

  • Patrick Y. Wen

  • Igor J. Barani

  • Fabio Massaiti Iwamoto

  • Raju R. Raval

  • Alfredo Daniel Voloschin

  • John Frederick De Groot

  • Minhee Won

  • Minesh P. Mehta

Medical Centers

  • University Hospitals Case Medical Center, Cleveland, OH

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • NRG Oncology Statistics and Data Management Center, Philadelphia, PA

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

  • University Hospital of Cleveland, Cleveland, OH

  • Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA

  • University of California, San Francisco, San Francisco, CA

  • Columbia University Medical Center, New York, NY

  • Ohio State University Wexner Medical Center, Columbus, OH

  • Emory University, Atlanta, GA

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • University of Maryland Medical Center, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02311920

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved